HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Sean Lee upgrades Dogwood Therapeutics (NASDAQ:DWTX) from Neutral to Buy and announces $10 price target.
HC Wainwright & Co. analyst Sean Lee upgrades Dogwood Therapeutics (NASDAQ:DWTX) from Neutral to Buy and announces $10 price target.